Navigation Links
Derma Sciences' MEDIHONEY(TM) Proven to Speed Healing in Stalled Leg Ulcers
Date:9/15/2008

Randomized controlled study finds significant healing and anti-infective

benefits, providing hope for patients and caregivers

PRINCETON, N.J., Sept. 15 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI) announced today that its key product, MEDIHONEY(TM) Wound & Burn Dressing with Active Leptospermum Honey, has been found in a large randomized controlled clinical trial to significantly improve the healing rates of stalled venous leg ulcers. Prior to this study, no other advanced wound care dressing, under compression therapy, had been shown to improve healing rates of leg ulcers. Physicians treat over 4 million leg ulcers in the US per year, at a cost exceeding $1 billion.

The trial, a 108-patient randomized and controlled clinical trial, looked at venous leg ulcers that had been proven to be non-healing under standard treatment (compression therapy). In the study, half the patients had a common advanced wound care gel added to the standard treatment, and half had Comvita's Active Leptospermum (Manuka) Honey (now marketed under the brand name MEDIHONEY) added. After four weeks, the mean reduction in size of the wounds was 34% in the honey group and 13% in the control group. After 12 weeks, there was a 44% complete healing rate in the honey group vs. only 33% in the control group. Both these differences were statistically significant.

The findings were published in the Journal of Clinical Nursing, and were written by lead investigators Georgina T. Gethin and Seamus Cowman, both of the Royal College of Surgeons in Ireland. They concluded that, "the [honey] group had shown a greater incidence of healing, more effective desloughing, and lower incidence of infection than the control group."

CEO Ed Quilty stated, "We are pleased that this important finding has been recognized in such a well-regarded peer reviewed journal serving the global market. Since the product's launch in Europe a couple of years ago, and then the launch in the US and Canada this year, clinicians have consistently reported that MEDIHONEY is effective on stalled ulcers of various etiologies. The recently published study now provides clear evidence of this by demonstrating results proven in a rigorous randomized controlled study. Clinicians can now feel confident in the value that they place on MEDIHONEY and the role it has to play in an overall treatment strategy.

This is significant for our product as currently, only 50% of chronic wounds heal with first-line treatment options. It is also significant for patients who suffer the effects of notoriously painful leg ulcers, with uncommonly long durations - sometimes lasting years."

Wound care is a major healthcare market with an estimated value of $10 billion in 2007 that is expected to grow to $12.5 billion by 2012. The global growth is being driven by several factors, including an aging population, the rise in the global incidence of diabetes and chronic vascular disorders, and a steady advancement in wound care technologies.

The Journal of Clinical Nursing (JCN) is an international, peer reviewed, scientific journal that seeks to promote the development and exchange of knowledge that is directly relevant to all spheres of nursing practice. The primary aim is to promote a high standard of clinically related scholarship which supports the practice and discipline of nursing. JCN publishes high quality papers on issues related to clinical nursing, regardless of where care is provided. This includes - but is not limited to - ambulatory care, community care, family care, home, hospital, practice, primary and secondary, and public health.

For more information on the Journal of Clinical Nursing, please visit: http://www.blackwellpublishing.com/journal.asp?ref=0962-1067

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound- care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey- based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. Derma has two products in development: the BIOGUARD(TM) line of barrier gauze dressings, and DSC127, the company's novel angiotensin analog for accelerated wound healing and scar reduction. The barrier technology was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA marketing clearance. DSC127 was licensed from The University of Southern California in Q4 of 2007 and is entering into a Phase II study, with anticipated initial patient enrollment to begin in Q3 of 2008. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

Contact: Derma Sciences, Inc. Allen & Caron Inc

Edward J. Quilty Rudy Barrio (US Investors)

Chairman and CEO r.barrio@allencaron.com

equilty@dermasciences.com

(609) 514-4744 Brian Kennedy (media)

brian@allencaron.com

(212) 691-8087


'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
2. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
3. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
4. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Neupro(R) (Rotigotine Transdermal System) Effective in Controlling Early Morning Motor Impairment and Generally Well-Tolerated for Long-Term Use in Patients with Parkinsons Disease
7. Rotigotine Transdermal System Shows Significant Symptom Reduction and Tolerability in Patients with Restless Legs Syndrome
8. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
9. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
10. Derma Sciences to Enter Phase II Development of Wound Healing Product That May Use Bodys Own Naturally Occurring Stem Cells
11. Genetic Immunity Presents Clinical Data on DermaVir Patch Immune Therapy at 15th Annual Conference on Retroviruses and Opportunistic Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... NORTHBROOK, Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the ... joins Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... appointed General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):